Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
fda
life sciences
national
4
×
national blog main
national top stories
raleigh-durham blog main
4
×
raleigh-durham top stories
san francisco blog main
san francisco top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biogen
cancer
europe blog main
europe top stories
ipo
johnson & johnson
novartis
10x genomics
abbvie
accent therapeutics
aducanumab
What
fda
4
×
bio
roundup
activity
approvals
august
biogen
biotech
busy
cancer
cash
clamped
clearance
company
covid
crunch
days
decisions
delays
developing
devices
didn’t
drug
drugs
economic
eisai
end
fast
flags
goal
higher
incidence
including
ipo
isn’t
legacy
lorcaserin
loss
lot
market
Language
unset
4
×
Current search:
national
×
biotech
×
unset
×
" raleigh-durham blog main "
×
fda
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
